Abbvie Inc

NYSE: ABBV
$183.65
+$2.51 (+1.4%)
Real Time Data Delayed 15 Min.

ABBV Articles

The top analyst upgrades, downgrades and initiations seen on Wednesday included Allergan, Apple, Carnival, Ciena, Juniper Networks, Lockheed Martin, Plug Power, Take-Two Interactive Software, United...
There is great opportunity in healthcare. There is also quite a lot of risk. Politicians and consumers alike want lower drug prices. Patients want the best of the best options for devices,...
The January 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
AbbVie shares retreated after it released disappointing fourth-quarter financial results before the markets opened on Friday.
The December 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The top analyst upgrades, downgrades and initiations seen on Thursday included AbbVie, Agilent Technologies, Albermarle, Apple, Boeing, Cheniere Energy, First Solar, HCA, LabCorp, Lumber Liquidators...
The December 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
The November 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
The November 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
The October 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with one major exception.
The top analyst upgrades, downgrades and initiations seen on Tuesday included AbbVie, AMAG Pharmaceuticals, Crocs, HCA, Kellogg, Kosmos Energy, Mylan, Pandora Media and Square.
AbbVie released its third quarter financial results before the markets opened on Friday. The pharma giant said that it had $2.14 in earnings per share (EPS) and $8.24 billion in revenue, compared...
Encana, Hanesbrands, Abbvie, and Annaly Capital Management all posted new 52-week lows Thursday.
The October 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
These four top pharmaceutical companies have longstanding franchises with huge sales and revenues, and their dividend-paying stocks look like outstanding choices for worried investors to consider...